ASX Announcement | 5 March 2021
Noxopharm Limited (ASX:NOX)

Noxopharm Presents to H.C. Wainwright Global Life Sciences Conference

Sydney 5 March 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces that the CEO and Managing Director, Dr Graham Kelly, will present to the virtual *H.C. Wainwright Global Life Sciences Conference* on 9-10 March 2021.

Dr Kelly's presentation entitled "*Noxopharm Investor Presentation March 2021*" is attached.

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

-ENDS-

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome/septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network
E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions

made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.


NOXOPHARM
Noxopharm Limited (ASX:NOX)
INVESTOR PRESENTATION March 2021
Discover
Develop
Deliver
Dr Graham Kelly
CEO and Managing Director

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Latest News

LuPIN TRIAL. Major cancer conference hears NOX + Novartis drug combination delivers major survival benefit of median **19.7 months** in Stage 4 prostate cancer

IONIC TRIAL. IONIC study start pending ethics approval

DARRT-2 TRIAL. Study expanded into wide range of cancers. Hospital selection for multinational study being finalised with Part 1 of the study due to commence Q3 2021

NOXCOVID TRIAL. First 4 (of 5) dosage cohorts successfully completed. Veyonda found to be well-tolerated

BUSINESS DEVELOPMENT. BD team assembled to advise on anticipated commercial and transactional strategies

ABSCOPAL RESPONSE BREAKTHROUGH. Large US university confirms abscopal response dependent on a drug action that Veyonda possesses

CASH. Dec 2020 cap raise, exercised options, and 2019/2020 R&D rebate put **A$31.7M** in bank

Veyonda® breakthrough multiple-acting immunotherapy drug

Activates immune cells

Increases trafficking of activated immune cells



Source: Dana-Faber Cancer Institute

Blocks autophagy ⇩ abscopal responses

Inhibits inflammation

Converts **COLD** tumors to **HOT** tumors

Veyonda® Clinical program

LuPIN-1	Phase I/II trial	Veyonda + ^{177}Lu-PSMA (**Novartis**)
IONIC-1	Phase I/II trial	Veyonda + Opdivo® (**Bristol Myers Squibb**)
DARRT-2	Phase II trial	Veyonda + external radiotherapy
NOXCOVID-1	Phase Ib trial	Veyonda

LuPIN

Veyonda® + ^{177}lutetium-PSMA-617

An exciting new treatment for prostate cancer

LuPIN (Veyonda + Lu-PSMA-617



^{177}lutetium-PSMA-617. Acquired by Novartis (4th largest pharma company/**US$195 billion market cap**) in 2018 for **US$6 billion**

Lu-PSMA-617 is a radioactive drug injected IV and designed to deliver radiation to every prostate cancer cell throughout the body

A proposed new treatment for prostate cancer once the cancer has spread widely (metastatic disease)

But ……

Not curative

Variable response rates. ~1/3rd men have little or no response

LuPIN Study



QUESTION: would adding Veyonda boost the effectiveness of the Novartis drug, with more men responding as well as achieving significantly longer survival times?

Phase I/II study. St Vincent's Hospital Sydney. Prof Louise Emmett

56 men. Late-stage cancer. No remaining standard treatments. Anticipated median survival approximately 4.5 months

6 cycles. 6 weeks apart. ^{177}Lu-PSMA-617 (1 day) + Veyonda (14 days)

LuPIN: Interim Data Reporting

American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021

ANSWER: Yes, the combination of Veyonda and Lu-PSMA-617 looks to considerably more effective than Lu-PSMA-617 on its own (*based on published Phase 2 data*[1])

56 men

400 + 800 mg + 1200 mg Veyonda

Median Overall Survival:

19.7 months

a remarkable result for this late stage of the disease

Combination was well tolerated

Noxopharm believes this to be a potential major breakthrough in the treatment of Stage 4 prostate cancer

1. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.228

LuPIN: Interim Survival Data

Median overall survival = *time when half the patients have died and half still alive*

Three standard lines of drug therapy once prostate cancer becomes metastatic



Historical data[1] → ~ 4.5 months

^{177}Lu-PSMA-617 alone[2] → 13.3 months

^{177}Lu-PSMA-617 + Veyonda (56 patients)[3] → 19.7 months

1. Buonerba C, et al. (2014) Future Oncol 10:1353–60. 2. Hofman M, et al. (2018) Lancet Oncol 19, 825. 3. Noxopharm ASX announcement 15 Feb 2021

Potential opportunities for LuPIN



1. Novartis Oncology Pipeline Update June 2020

IONIC

Veyonda ® + nivolumab (Opdivo®)

Overcoming resistance to checkpoint inhibitors

IONIC Study

Phase I/II proof-of-concept study



DARRT

Veyonda ® + external beam radiotherapy

Making the rare abscopal response common-place

DARRT Direct and Abscopal Response to Radiotherapy

Veyonda®

- ☛ enhances the damaging effects of radiation in irradiated tumours

DIRECT RESPONSE

Veyonda®

- ☛ blocks autophagic repair of cell damage in irradiated tumours
- ☛ triggers systemic immune response in non-irradiated tumours

ABSCOPAL RESPONSE

DARRT

Veyonda selectively blocks sphingosine kinase in cancer cells, resulting in elevated ceramide and depressed S1P levels



DARRT: Treatment regimen

Low-dose radiotherapy to a single lesion

- ☛ external beam radiotherapy
- ☛ 8-30 Gy
- ☛ 1-10 fractionated doses
- ☛ single cycle of RT

Veyonda® (NOX66)

- ☛ 21-day cycle: daily dosing for 14 days (7 days rest)
- ☛ starting Day -1
- ☛ repeat monthly cycles (in DARRT-2) until disease progression [one cycle in DARRT-1]

DARRT-1 conclusions

- Veyonda® was safe and well tolerated
- Promising efficacy signals were obtained, including evidence of abscopal response in 4 patients
- Efficacy signals (pain response, PSA response)were maintained from 3 to at least 6 months

DARRT-2 Study Design

A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Part 1

Solid Tumours
3 Dose Cohorts
At least 2 mCRPC in each cohort

Primary Objective
- Safety
- MTD/RP2D

Part 2

mCRPC

NSCLC
Breast Cancer

Primary Objective
- PSA Response (mCRPC)
- DCR (Other Tumours)

Patient Population:
Patients who are eligible for low-dose EBRT for at least one symptomatic or minimally symptomatic lesion (for the prevention of symptoms).

Other Objectives
ORR, PFS, OS, Pain response, PK, Biomarkers, QOLs

OTHER UPDATES

LuPIN trial

Study ends Oct 2021. All treatments completed. Final Report expected Q1 2022

NOXCOVID trial

Part 1 (dose-escalation) complete. Part 2 to start March 2021

Drug pipeline

First-in-class drug with novel approach to treatment of brain cancer progressing enters pre-clinical testing

Pharmorage subsidiary

Major opportunity underway to develop new family of drugs for sepsis and autoimmunity

Our commercial end-point for Veyonda

A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity

Programs focusing on immuno-oncology and cell therapy remain the most attractive targets for partnering

In 2020, 52 deals >US$1 billion were transacted, 31 of these were for immuno-oncology and cell therapy assets and platforms

Key metrics

as at 4 March 2021



News Flow (next 6 months)

- IONIC-1 and DARRT-2 start patient recruitment
- COVID-19 clinical trial completion
- Growing first-in-class drug pipeline
- Pharmorage (subsidiary) progressing novel drug development for sepsis and autoimmunity


NOXOPHARM
For further information
email: info@noxopharm.com
web: www.noxopharm.com
twitter: @noxopharm
Discover
Develop
Deliver